Latest News and Press Releases

NEW YORK, July 17, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), today announced that it has appointed the members of its Nuclear...

Minimal Residual Disease is increasingly recognized as a primary driver of high AML relapse with a need for improved consolidation therapiesWebcast to be held on July 10, 2018 at 8:00 AM ET to discuss...

Minimal Residual Disease is increasingly recognized as a primary driver of high AML relapse rate highlighting need for improved consolidation therapies Webcast to be held on July 10, 2018 at 8:00 AM...

Iomab-B remains the only targeted conditioning treatment in clinical trials with the potential to increase access to and improve outcomes of bone marrow transplant              NEW YORK, June 26,...

Two Nuclear Medicine focused advisory boards have been formed to provide expertise and strategic guidance to Actinium  Meeting with Iomab-B and Actimab investigators to be held to provide trial...

- Trial supports Actinium’s strategic expansion of its CD33 program into novel combinations that can lead to increased use of bone marrow transplants and expand the addressable patient population for...

- Management to conduct business development and investor focused meetings at the conference NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN:ATNM)...

Dr. Chell led Be the Match and the National Marrow Donor Program for 17 years establishing these organizations as the largest volunteer bone marrow transplant donor registry in the world that...

- Dr. Vijay Reddy joins Actinium with over 20 years of bone marrow transplant clinical experience including extensive product development experience at Pharmacyclics, an AbbVie Company, Medimmune and...

- In vivo data to be presented via poster highlighting the ability of Actinium’s AWE Technology to yield increased cell killing power, survival benefit and a potential biobetter of daratumumab, a...